drugset / Trial / NCT05403749
A Study of Longer Interval of IVT IBI302 in Subjects With nAMD
RandomizedParallel-groupDouble-blindTreatment
Summary
The study is designed for multi-center, randomized, double-masked, active-controlled study to evaluate the longer interval of intravitreal injection of IBI302 in subjects with neovascular age-related macular degeneration.
Timeline
- Start
- 2022-06-29
- Primary completion
- 2024-05-13
- Completion
- 2024-05-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Other |
| Subject | IBI302 | Unknown | — | Other |